Hidradenitis Suppurativa clinical trials at UC Davis
1 research study open to eligible people
Experimental Risankizumab vs. Placebo For Moderate to Severe Hidradenitis Suppurativa (painful lumps under skin)
open to eligible people ages 18 years and up
This study is to evaluate the safety and efficacy of 2 dose levels of risankizumab in adult participants with moderate to severe Hidradenitis Suppurativa (HS). This study includes two treatment periods. In Period A, participants are randomized to receive either risankizumab dose A, dose B, or placebo. In Period B, participants who received risankizumab dose A or placebo during Period A, will receive risankizumab dose B. Participants who received risankizumab dose B in Period A will remain on that dose in Period B.
Sacramento, California and other locations